Letter to the Honorable John Carey

Letter to the Honorable John Carey, Chairman of the Senate Committee on Finance and Financial Institutions in Ohio from BIO, regarding House Bill 66.

Letter to Governor Deval Patrick

BIO letter to Governor Deval Patrick of Massachusetts regarding concerns about Senate Bill 2863.

BIO Testimony regarding Oregan Senate Bill 570

Testimony to the Oregon Senate Environment & Land Use Committee regarding The Oregon Genetically Engineered Pharmaceutical and Industrial Crop Act.

Questions for the District of Columbia Board of Pharmacy for the drafting of SafeRx

Frequently Asked Questions Document

Clinical Trials: ICTRP guidelines

BIO urges the ICTRP to focus on developing a procedure that would address the need to balance the incentive to innovate with the need to provide patients and health care providers with the information they need in order to assess the availability and suitability of a clinical trial.

Clinical Trials: Review of the Declaration of Helsinki

BIO’s comments on the World Medical Association’s (WMA’s) Declaration of Helsinki.

Request for Comment Extension RE: Docket No. APHIS-2014-0054 – Environmental Impact Statement; Introduction of the Products of Biotechnology

We, the undersigned organizations, appreciate the opportunity to provide comment on APHIS’ Notice of Intent (NOI) to prepare an environmental impact statement in connection with potential changes to APHIS biotechnology regulations (7 CFR 340). Our member organizations represent a broad cross-section of stakeholders having a significant interest in the future of U.S. agriculture, including farmers, grower groups, handlers, marketers, processors, manufacturers, distributors and exporters of agricultural products, as well as seed companies and technology providers.

BIO 2016 Special 301 Submission

The Biotechnology Innovation Organization (BIO) appreciates the opportunity to comment on the 2016 Special 301 Submission. 

BIO Comments on FDA voluntary labeling of GE salmon

Food and Drug Administration Docket No. FDA-2015-D-4272; Food Labeling; Voluntary Labeling Indicating Whether Food Has or Has Not Been Derived From Genetically Engineered Atlantic Salmon; Draft Guidance for Industry.

BIO Submits Comments Re: MIPS, Promotion of Alternative Payment Models, and Incentive Payments for Participation in Eligible Alternative Payment Models RFI

RE: CMS Regarding Implementation of the Merit-Based Incentive Payment System, Promotion of Alternative Payment Models, and Incentive Payments for Participation in Eligible Alternative Payment Models